Astrazeneca PLC (AZN) Downgraded by Liberum Capital
Liberum Capital downgraded shares of Astrazeneca PLC (NYSE:AZN) from a buy rating to a hold rating in a report published on Thursday, MarketBeat reports.
Several other research firms have also issued reports on AZN. Leerink Swann reissued an outperform rating and set a $36.00 price objective (up previously from $33.00) on shares of Astrazeneca PLC in a research note on Wednesday, May 17th. Investec raised Astrazeneca PLC from a hold rating to a buy rating in a research note on Wednesday, August 9th. Barclays PLC reissued an overweight rating on shares of Astrazeneca PLC in a research note on Monday, July 3rd. Argus reissued a buy rating and set a $35.00 price objective on shares of Astrazeneca PLC in a research note on Friday, September 1st. Finally, Goldman Sachs Group, Inc. (The) reissued a sell rating on shares of Astrazeneca PLC in a research note on Thursday, July 13th. Four equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and twelve have given a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus price target of $33.60.
Astrazeneca PLC (NYSE AZN) opened at 32.53 on Thursday. The firm has a market cap of $82.37 billion, a PE ratio of 21.34 and a beta of 0.74. Astrazeneca PLC has a 12-month low of $25.55 and a 12-month high of $35.60. The stock’s 50 day moving average price is $30.20 and its 200-day moving average price is $31.74.
Astrazeneca PLC (NYSE:AZN) last posted its quarterly earnings data on Thursday, July 27th. The company reported $0.87 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.41 by $0.46. The company had revenue of $5.05 billion during the quarter, compared to analyst estimates of $5.04 billion. Astrazeneca PLC had a return on equity of 35.90% and a net margin of 17.80%. The firm’s quarterly revenue was down 9.9% on a year-over-year basis. During the same quarter last year, the company earned $0.83 earnings per share. Equities research analysts anticipate that Astrazeneca PLC will post $1.90 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece of content was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/17/astrazeneca-plc-azn-downgraded-by-liberum-capital.html.
The firm also recently declared a None dividend, which was paid on Monday, September 11th. Investors of record on Friday, August 11th were issued a dividend of $0.44 per share. The ex-dividend date of this dividend was Wednesday, August 9th. This represents a yield of 2.98%. Astrazeneca PLC’s dividend payout ratio is presently 44.92%.
Several hedge funds have recently bought and sold shares of AZN. Meeder Asset Management Inc. purchased a new position in shares of Astrazeneca PLC during the 2nd quarter worth approximately $105,000. Salem Investment Counselors Inc. purchased a new position in shares of Astrazeneca PLC during the 1st quarter worth approximately $107,000. Tower Research Capital LLC TRC grew its holdings in shares of Astrazeneca PLC by 3,782.0% during the 1st quarter. Tower Research Capital LLC TRC now owns 3,882 shares of the company’s stock worth $121,000 after acquiring an additional 3,782 shares during the period. WFG Advisors LP grew its holdings in shares of Astrazeneca PLC by 36.0% during the 2nd quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock worth $127,000 after acquiring an additional 984 shares during the period. Finally, Parallel Advisors LLC grew its holdings in shares of Astrazeneca PLC by 27.1% during the 1st quarter. Parallel Advisors LLC now owns 4,526 shares of the company’s stock worth $138,000 after acquiring an additional 964 shares during the period. Hedge funds and other institutional investors own 14.18% of the company’s stock.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.